FDA Approved: ATELVIA — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved Allergan's supplemental application for Atelvia (risendronate sodium), a delayed-release bisphosphonate, with updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• ATELVIA (RISENDRONATE SODIUM)

Snippet

SUPPL AP for ATELVIA (RISEDRONATE SODIUM)